It was reported that CSF SNAP-25 could differentiate AD from PD, FTD and ALS, and high concentration of CSF SNAP-25 could be applied as a biomarker for both AD and CJD (Halbgebauer et al., 2022a). This evidence concerns the gene SNAP25 and Creutzfeldt Jacob disease.